Fast screening of 88 pharmaceutical drugs and metabolites in whole blood by ultra-high performance liquid chromatography - tandem mass spectrometry by Vincenti, Marco et al.
15 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Fast screening of 88 pharmaceutical drugs and metabolites in whole blood by ultra-high performance liquid





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript





This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 
Analytical Bioanalytical Chemistry, 405, 2-3, 2013, DOI: 10.1007/s00216-012-6403-y 
M. Vincenti, D. Cavanna, E. Gerace, V. Pirro, M. Petrarulo, D. Di Corcia, A. Salomone 
volume 405, Springer, 2013, 863-879 
 
The definitive version is available at: 











Forensic investigations involving acute or lethal intoxication, drug-facilitated sexual assault, driving 
or workplace impairment frequently require the analysis of fresh or postmortem blood samples to 
check out a wide variety of pharmaceutical and illicit drugs, even after single-dose consumption. A 
sensitive and selective ultrahigh-performance liquid chromatography–tandem mass spectrometry 
UHPLC–MS/MS) screening method was developed for fast screening of 88 psychoactive drugs 
and metabolites in blood samples, including the ones most frequently involved in acute 
intoxications  and forensic investigations in Italy. The new method allows short sample processing 
and analysis time (the whole procedure can be accomplished in less than 30 min) together with the 
simultaneous monitoring of a large number of pharmaceutical substances. These features 
represent crucial factors in the approach of acute intoxications, when the patient requires urgent 
and appropriate therapy. Blood sample treatment was limited to protein precipitation. Two UHPLC–
MS/MS runs in positive and negative electrospray ionization modes were performed. The data 
were acquired at unit mass resolution in the selected reaction monitoring mode. According to 
international guidelines, linearity range, precision, trueness, detection and quantification limits, 
recovery, selectivity, specificity, carryover, and matrix effect phenomena were determined. Despite 
the limited sample purification and the inherent decreased chance of eliminating any potential 
interference, the present multiresidue screening method proved extremely effective and sensitive, 
allowing the detection of all tested drugs, even those belonging to structurally different classes of 
substances. Moreover, the developed method is easily susceptible to further expansion to 
encompass more drugs, either new or those becoming important for criminal investigation. This 
protocol was also applied to the analysis of authentic blood samples collected from victims of 
















Several matters of forensic investigations involve the need for toxicological analysis, including 
lethal intoxication (suicide or homicide), abuse of pharmaceutical and/or illicit drugs, driving or 
workplace impairment, and drug-facilitated sexual assault. In all these cases, the analysis of 
biological matrices is carried out to check the possible presence of a wide variety of substances, or 
to exclude any hypothetical role played by drugs in the specific crime context [1]. 
Urine is the best specimen for comprehensive drug and poison screening, especially in the cases 
when the circumstantial elements are unknown [2]. Urinary excretion of the taken drug or poison 
may result in high concentration, making it more easily detectable than in blood specimen, for a 
longer period of time. However, the drug metabolites have to be identified additionally or, in some 
cases, exclusively. On the other hand, blood (plasma, serum, or whole blood) is the matrix of 
choice for drug quantification in forensic investigations because pharmacological and toxic effects 
can be related to its concentration in the bloodstream. Therefore, the detection of toxic substances 
in either fresh or postmortem blood samples offers the chance of interpreting their role in terms of 
acute intoxication or impairing effects at the time of blood sampling or death [3–5]. In most cases, 
only a limited amount of blood sample is available, and a wide range of endogenous components 
is present. Whenever these analytes are not known in advance or interferents are present, 
preliminary multi-target screening procedures proved to be necessary before accurate 
quantification [1]. Screening methods based on immunoassay testing are available only for few 
classes of drugs [6–8]—such as cannabinoids, cocaine, amphetamines, opiates, methadone, 
benzodiazepines, barbiturates, and tricyclic antidepressants—whereas no immunoassays are 
commercially available for the newest designer drugs [1] and other common substances, including 
anesthetics, antihistamines, and sedative–hypnotics [4]. Moreover, the use of multiple 
immunoassays testing requires a considerable amount of blood samples. Conversely, novel 
comprehensive multianalyte procedures based on hyphenated chromatography and tandem mass 
spectrometry are capable to detect simultaneously many drugs at once in a small sample volume, 
and provide systematic toxicological analysis [5, 9–14] for competent toxicological judgments and 
expertise in forensic investigations [13, 15]. Although gas chromatography–mass spectrometry 
(GC– MS) has been extensively used in the past [5, 16–18], nowadays, liquid chromatography–
tandem mass spectrometry (LC–MS/MS) is replacing GC–MS as the standard technique for 
comprehensive screening methods in forensic laboratories [13, 14, 19–22], and in-house MS/MS 
libraries are successfully implemented [10, 23–25]. Increasing performances and decreasing costs 
of such instrumentation [5] have rapidly and deeply expanded the multi-residue capability of LC–
MS/MS protocols, with significant benefit for drug screening in blood samples [8, 12, 26–30]. 
Moreover, ultrahigh-performance liquid chromatography (UHPLC) guarantees shorter analysis time 
and improved chromatographic resolution [5]. A wide variety of substances of toxicological interest 
can be detected in a single run [31], provided that nonselective extraction procedures are utilized 
to reduce matrix effects and potential interferences. For example, protein precipitation is always 
required and provides good recovery also for polar analytes, unlike most SPE and LLE procedures. 
Protein precipitation, followed by LC–MS/MS, was utilized to achieve simple, fast, and cheap 
screening analyses, with high sample throughput [32]. 
The objective of our study was to develop and validate a fast UHPLC–MS/MS screening method 
for the determination of 88 psychoactive drugs and metabolites in whole blood samples, including 
the substances most frequently involved in forensic investigations in Italy. Drugs of abuse were not 
included since they are often screened separately, either with immunological tests or LC–MS/MS 
procedures, as in our laboratory. Our validation process included the determination of linearity 
range, selectivity, specificity, detection and quantification limits (LOD and LOQ), intra-assay 
precision, trueness, recovery, matrix, and carryover effects. The method was successfully applied 
to the analysis of blood samples in routine casework and proved valuable and easily adaptable in 
both forensic and clinical investigations; namely, it can be promptly updated to include emerging 




Reagents and materials 
All 88 reference substances were purchased from either LGC Promochem SRL (Milan, Italy) or 
Sigma-Aldrich (Milan, Italy). Dichloromethane, methanol, formic acid, and acetonitrile were 
provided by Sigma-Aldrich (Milan, Italy). Ultra-pure water was obtained using a Milli-Q® UFPlus 
apparatus (Millipore, Bedford, MA, USA). Stock standard solutions were stored at −20 °C until 
used. Four compounds were used as the internal standards (IS), including two isotopically marked 
molecules (cocaine-d3 and nitrazepam-d5), together with coumachlor and althiazide, namely two 
substances currently not commercialized in Italy nor reported within human blood samples in the 
forensic and clinical literature. Three working solution mixtures were prepared by dilution in 
methanol at final concentrations of respectively 1 μg/mL (working solution A), 5 μg/mL (working 
solution B), and 10 μg/mL (working solution C). The inclusion of each analyte into the respective 
working solution was decided according to the upper limit of its therapeutic concentration interval 
[33–35], which is reported in Table 2 (<100 ng/mL, from 100 to 1,000 ng/mL, and >1,000 ng/mL, 
respectively for working solutions A, B, and C). Lastly, an internal standard mixture working 
solution was prepared in methanol, including cocaine-d3, nitrazepam-d5, and coumachlor at the 
final concentrations of 2 μg/mL, and althiazide at 4 μg/mL. Sample preparation Each aliquot of 
whole blood (0.5 mL) was fortified with 25 μL of internal standard mixture to yield a final 
concentration of 100 ng/mL (200 ng/mL for althiazide). One milliliter of acetonitrile/methanol 80:20 
(v/v), previously stored at −20 °C, was added to the sample, which was then incubated at −20 °C 
for 5 min. Afterwards, the sample was centrifuged at 4,000 rpm for 15 min, and 50 μL of the 
organic phase was transferred into a new vial. Finally, the vial was centrifuged once more at 
14,000 rpm for 5 min, and a 1-μL aliquot was directly injected into the UHPLC–MS/MS system. 
 
Instrumentation 
All analyses were performed on a Shimadzu Nexera 30 UHPLC-system (Shimadzu, Duisburg, 
Germany) interfaced to an AB Sciex API 5500 triple quadrupole mass spectrometer (AB Sciex, 
Darmstadt, Germany) with an electrospray Turbo Ion source operating in the positive (ESI+) and 
negative (ESI–) ion modes, in two separate chromatographic runs. A Zorbax XDB-C18 column 
100×2.1 mm i.d.×1.8 μm (Agilent Technologies, Italy), protected by a C18 guard column, was used 
for the separation of analytes. The column oven was maintained at +50 °C, and the elution 
solvents used were water/formic acid 5 mM (solvent A) and acetonitrile (solvent B). The mobile 
phase eluted under the following linear gradient conditions (a/b; v/v): from 95:5 to 37:63 in 6.0 min, 
then to 10:90 at 6.1 min with isocratic elution at 90 % B for 1.0 min. The flow rate was 0.5 mL/min 
and total time of the run was 10.0 min, so as to ensure re-equilibration at the initial conditions in 
between two consecutive injections. Data were recorded in the selected reaction monitoring mode 
(SRM). In order to establish appropriate SRM conditions, each analyte was individually infused into 
the ESI capillary, and the declustering potential (DP) was adjusted to maximize the intensity of the 
protonated molecular species [M+H]+ and [M–H]–. Conversely, the entrance potential was fixed at 
±10 V (for ESI + and ESI–, respectively) for all the analytes. The collision offset voltage (CE) was 
adjusted to preserve approximately 10 % of the precursor ion, and the cell exit potentials (CXP) 
were also optimized. Each SRM transition was maintained during a time window of ±10.0 s around 
the expected retention time of the corresponding analyte, and the SRM target scan time (i.e., sum 
of dwell times for each SRM cycle) was 0.20 s, including pause times of 5 ms between consecutive 
SRM transitions. The best results were obtained using a source block temperature of +550 °C and 
an ion-spray voltage of ±3,000 V (for ESI+ and ESI–, respectively). Both Q1 and Q3 were operated 
at unit mass resolution. Nitrogen was employed as the collision gas at 0.005 Pa. The gas settings 
were as follows: curtain gas 27.0 psi, collision gas 10.0 psi, ion source gas (1) 50.0 psi, and ion 
source gas (2) 40.0 psi. The Analyst 1.5.2 (AB Sciex) software was used for data processing. All 
analytes and internal standards, their corresponding retention time, SRM transitions, and potentials 
are presented in Table 1. 
 
Validation 
The analytical method was validated in accordance with the criteria and recommendations of 
ISO/IEC 17025:2005 international standard. The following parameters were investigated: 
selectivity, linearity range, LOD and LOQ, intra-assay precision, trueness, and recovery. Carryover 
and matrix effect phenomena were also evaluated. Whole blood combined with EDTA as a 
preservative was collected from volunteers and used as the working matrix for all validation 
experiments. Identification criteria and repeatability of diagnostic fragment ions’ relative 
abundances Identification criteria for the analytes were established according to national [36] and 
international [37–39] guidelines. Retention time is part of the acceptance criteria for 
chromatographic assays. In particular, deviations of 1–2 % from the calibrators or controls are 
acceptable for HPLC based assays. When mass spectrometry is used for the identification of an 
analyte, the use of at least one qualifying mass transition for each analyte, in addition to the 
primary fragmentation, is recommended. Variations of mass transitions intensities were considered 
acceptable if within ±20 %, comparatively to the corresponding control. The repeatability of relative 
peak intensities for the SRM transitions of each analyte was determined on five spiked fresh blood 
samples at three concentration levels (5, 25, and 75 ng/mL for working solution A; 25, 75, and 150 
ng/mL for working solution B; and 50, 150, and 300 ng/mL for working solution C). Retention time 
(tR) precision at each concentration was also determined.  
 
Selectivity and specificity 
Five fresh blank blood samples from different donors were analyzed to test the selectivity of the 
whole analytical procedure. For each sample and all analytes, the signal to noise ratio (S/N) was 
measured for the corresponding mass transitions at the expected retention time windows. A ratio 
S/N <3 was considered satisfactory in order to verify the method specificity. 
 
Linearity range 
The linear calibration model was checked by analyzing (two replicates) whole blood samples 
spiked with working solutions at six final concentrations, covering different ranges according to the 
therapeutic interval of each analyte. More in detail, the intervals 2–75 ng/mL (2, 5, 10, 25, 50, and 
75 ng/ml), 10–150 ng/mL (10, 25, 50, 75, 100, and 150 ng/ml), and 20–300 ng/mL (20, 50, 100, 
150, 200, and 300 ng/ml) were investigated for the working solutions A, B, and C, respectively. The 
calibration was completed by internal standardization. The linear calibration parameters were 
obtained using the least squares regression method. The squared correlation coefficient (R2) was 
utilized to roughly estimate linearity. 
 
Detection and quantification limits 
The limit of detection (LOD) was calculated as the concentration of the analyte that gives a signal 
(peak height) equal to the average background of the blank (Sblank) plus three times its standard 
deviation (LOD0Sblank+3Sblank), while the LOQ was calculated as LOQ0Sblank+10Sblank. The 
noise was measured from ±0.05 min before the peak onset till the beginning of the peak for each 
analyte. The LOD values estimated from calculation were experimentally confirmed by analyzing 
five blank blood samples spiked with all analytes at the concentrations approximately 
corresponding to their estimated LOD values. 
 
Intra-assay precision and trueness 
For all analytes, intra-assay precision (CV%) and trueness (expressed as bias percentage) were 
evaluated by extracting and analyzing five whole blood samples spiked at three concentration 
levels (5, 25, and 75 ng/mL for working solution A; 25, 75, and 150 ng/mL for working solution B; 
and 50, 150, and 300 ng/mL for working solution C). Although the acceptance criteria for precision 
and trueness are not fixed for screening methods by internationally standardized rules, it was 
established that intra-assay precision was satisfactory when CV% values were below 25 %. 
Satisfactory trueness was achieved when the experimentally determined average concentration 
lied within ±25 % from the expected value. 
 
Extraction recovery and matrix effect 
The extraction recoveries and matrix effects were calculated by comparing the experimental results 
from two sets of solutions [40, 41] at three different concentrations (5, 25, and 75 ng/mL for 
working solution A; 25, 75, and 150 ng/mL for working solution B; and 50, 150, and 300 ng/mL for 
working solution C). The analytes’ recovery was calculated by the ratio between the analyte blood 
concentration determined after its extraction (first set) and the one determined on the spiked 
extract (second set). The matrix effect was calculated as the percentage ratio between the analyte 
chromatographic peak area detected from the second set (blood samples spiked after the 
extraction step) and that detected from the third set (spike after the extraction step on blank 
deionized water). The percentage difference highlighted matrix suppression (values below 100 %) 
or enhancement (values above 100 %).  
 
Carryover effect 
Carryover effect was evaluated by injecting an alternate sequence of five blank blood samples and 
five blank blood samples spiked with all the analytes at high concentrations (up to 75, 150, and 300 
ng/mL for the working solutions A, B, and C, respectively). To ensure the absence of any carryover 





Results and discussion 
UHPLC–MS/MS method 
Preliminary experiments were conducted to verify that a wide range of substances with 
considerably different chemical structures and physical properties could simultaneously be 
collected after protein precipitation and determined within instrumentally compatible conditions. 
These experiments confirmed that the proposed sample treatment was mild enough to not 
extensively remove any of the studied substances, but also showed that seven of these drugs were 
much more effectively detected by using the negative rather than the positive ion mode. The final 
optimized UHPLC–MS/MS method allowed the determination of all 88 analytes and 4 internal 
standards using two consecutive chromatographic runs under ESI+ and ESI− conditions, 
respectively. Each chromatographic run was completed in 10 min, including the time required for 
column re-equilibration before the next injection. The list of pharmaceutical drugs included in the 
screening represents the molecules most frequently involved in forensic investigations in Italy, as a 
result of the drugs present in the Italian market and their prescription frequency (i.e., number of 
packaging sold). More in detail, the investigated analytes belong to various classes of drugs, as 
follows: 13 analgesics, 1 antitussive, 1 β-blocker agent, 9 anxiolytics, 11 antipsychotics, 1 
antihistame, 9 antidepressants, 3 nonsteroidal anti-inflammatory agents, 1 antiemetic, 1 
anthelminthic, 1 barbiturates, 1 antigastric agent, 3 antihypertensive drugs, 3 anticholinergic 
agents, 3 PDE5 inhibitors, 2 anesthetics, 2 anticonvulsants, 1 antidiarrheal opioid agonist, 1 
psychostimulant, 6 benzodiazepines, zolpidem, zopiclone, methadone, scopolamine, and 8 
metabolites. Their retention times ranged from 1.00 to 5.70 min for the chromatographic run 
conducted in ESI+, and from 2.30 to 5.90 min for the run conducted under ESI− conditions. Figure 
1a–e shows the SRM chromatograms recorded from a whole blood sample, spiked with all 
analytes at 50 ng/mL concentration. Only one SRM transition is depicted for each analyte. Two 
SRM transitions were utilized to detect the target analytes, as is recommended by national [36] and 
international guidelines [37–39]. Although product ion spectra could be recorded on triple 
quadrupole instruments to better sustain drug identifications, we decided not to use this option in 




Identification criteria and selectivity 
In order to detect each analyte, two SRM transitions were selected, as summarized in Table 1. 
This, together with the retention time, provides sufficient identification points to achieve 
unequivocal recognition of the analytes [36, 37, 39]. The intra-assay precision for the retention 
times measured at low, medium, and high concentrations showed random fluctuations, but always 
within ±1.0 %, confirming that the retention times were repeatable and not affected by the analytes’ 
concentration. An important parameter to obtain repeatable retention times proved to be the 
temperature control of the UHPLC column, which was maintained at +50 °C. In a multianalyte 
screening method, retention time repeatability is a particularly important criterion for compounds 
identification. Furthermore, for each analyte the relative abundance of the two selected SRM 
transitions varied by less than ±20 % so proved compliant for the unambiguous identification of all 
analytes included in the assay. The SRM chromatograms from five blank blood samples taken 
from different individuals showed no interfering signals (i.e., S/N ratio minor than 3) at the expected 
retention time, for all the analytes, except for diltiazem. This demonstrates that the method is 
selective for almost all tested compounds and free from positive interferences. The only non-
compliant result, observed for diltiazem, does not compromise the general applicability of the 
screening method on real forensic and clinical cases. In fact, this compound, usually found as a 
cocaine adulterant, exhibits an average S/N040±1 in blank samples. This interfering signal is 
negligible in comparison with the S/N074 obtained at the detection limit (0.40 ng/mL), which in turn 
is much lower than the therapeutic level (50–200 ng/mL). 
 
Linearity and evaluation of LOD and LOQ 
All the calibration plots, built from spiked blank blood samples at five or six concentration levels 
and extending for more than one order of magnitude, showed good linearity. Table 2 reports the 
resulting R2 values that range from 0.985 and 0.999 and roughly indicate good fit and linearity of 
the calibration curves, with respect to the screening purpose of the method. Table 2 also reports 
LOD and LOQ values, calculated from the analysis of five blank samples and confirmed 
experimentally by the analysis of blank samples spiked with the analytes at concentrations 
approximating LOD values. In these experiments, all analytes were clearly detected. LOD values 
lay between 0.04 (sufentanil) and 15.00 ng/mL (barbital), LOQ values between 0.13 and 50.00 
ng/mL (sufentanil and barbital, respectively). For all analytes, both LOD and LOQ values are 
significantly lower than the corresponding therapeutic levels, confirming that the present method is 
highly reliable for screening purposes and scarcely susceptible of yielding false negative results, 
possibly even after a single-dose consumption.  
 
Intra-assay precision and trueness 
Intra-assay data on precision and trueness are reported in Table 3. The results demonstrated 
satisfactory intra-assay precision, at least at “medium” and “high” concentration levels, as the 
percent variation coefficient (CV%) is lower than 25 % for almost all analytes, from 25 to 300 
ng/mL, for working solutions B and C. Only norfentanyl, norbuprenorphine, and paroxetine 
presented an unsatisfactory CV% value (>25 %) at more than one concentration level. Almost all 
CV% values exceeding 25 % are relative to samples spiked at 5 ng/mL (or “low level”), namely a 
concentration largely below the therapeutic intervals and rarely observed in real samples of 
forensic interest. At the low level concentration, 66 out of 88 drugs proved compliant with intra-
assay precision requirements (67 %), whereas 88/88 (100 %) and 85/88 (96 %) drugs were 
compliant at medium and high concentrations, respectively. Intra-assay precision apparently 
improves with the absolute analytes’ concentration: in fact, 100 % compliant values are observed 
at 150 and to 300 ng/mL concentrations. The trueness, expressed as percent bias, varied from 
excellent for some analytes to unsatisfactory for other compounds (Table 3). For example, 
clonazepam and levamisole exhibited a brilliant +0.1 % bias, at 25 and 150 ng/mL concentrations, 
respectively. On the other side, positive and negative bias as high as +397.2 % and −38.1 % were 
observed for ibuprofen at 50 ng/mL and alfentanil at 5 ng/mL, respectively. Overall, 45 out of 88 
drugs showed compliant trueness at all concentration levels, while the rest of them (43 out of 88) 
proved not compliant at least at one concentration level. These results demonstrate that an 
additional semi-quantitative information can be achieved only for the analytes with satisfactory 
precision and trueness, despite the present method is mainly intended for screening purposes, and 
rough estimation of blood concentration can be obtained for all the drugs included in the present 
study. On the whole, the majority of experimental biases were within the acceptable limit of 25 % at 
all concentrations, ranging from 5 to 300 ng/mL. The reasons for observing a few unsatisfactory 
trueness values are likely to be found in both the unselective sample treatment, possibly leaving 
co-eluting extraneous substances capable of signal suppression or enhancement, and the use of a 
limited choice of internal standards for quantification. Nevertheless, overestimated and 
underestimated results do not compromise the general applicability of this screening method since 
all positive samples have to be newly processed with more accurate and exact confirmation 
analyses.  
 
Extraction recovery and matrix effect 
For each analyte, extraction recovery and matrix effect results are shown in Table 3. The average 
extraction recovery is around 60 %, with the minimum observed value of 22.1 % for 
norbuprenorphine at 25 ng/mL, and the maximum value equal to 86.5 % for lidocaine at 300 
ng/mL. Low recovery values are likely to be due to the generic conditions adopted in the extraction 
procedure, possibly yielding partial adsorption and co-precipitation of the analytes within the 
proteic matter. However, none of the recovery values is too low to prevent the detection of the 
corresponding analyte, so that the wide screening capability of the present method turns out not to 
be affected. Moreover, the low concentration levels under investigation are considerably lower than 
those expected in real samples, around the therapeutic range. In the practical situations, the 
observed extraction recoveries are sufficiently large and repeatable to allow the unequivocal 
identification of all target substances. For almost all analytes, the matrix effect is negative, i.e., 
signal suppression is observed. The highest negative effect is seen for norbuprenorphine at 25 
ng/mL (−88.3 %), while the largest positive value is +22.2 % for scopolamine at 75 ng/mL. On 
average, the matrix effect is estimated around −33 %. Ion suppression is quite common in ESI, 
whenever complex mixtures are studied, since the co-elution of analytes and extraneous 
substances makes the competition for the charge dependent on their relative chemical and 
physical properties. In the present case, the modest blood sample cleanup and the co-elution of 
some analytes, due to the short chromatographic run, are most likely to produce the observed 
matrix effect [42]. In particular, protein precipitation does not completely remove the endogenous 
substances, such as lipids, phospholipids, and fatty acids, that may affect the ESI droplet 
desolvation process [43]. However, signal suppression does not affect significantly the detection 
capability in this method since LOD values for all analytes are still lower than the expected 
concentrations in real blood samples. Some analytical parameters such as intra-assay precision 
and trueness are likely to be affected by the use of a limited number of internal standards, in 
combination with differential matrix effects. Nevertheless, the use of a huge number of internal 
standards increases the number of monitored analytes and the cost of this screening method. 
Therefore, semi-quantitative results obtained from the present screening method are then 
corrected by running confirmatory procedures with appropriate and carefully selected, i.e., 
isotopically labeled, internal standards. 
 
Carryover effect 
No carryover effect was observed under the conditions described in the “Experimental” section. 
Blank blood samples, alternatively analyzed with samples spiked at high concentration (up to 300 
ng/mL), showed S/N values always lower than 3 at the retention times of the tested analytes. As 
for selectivity testing, diltiazem was the only analyte showing S/N>3 (45.2±2.3). However, the 
recorded S/N value is substantially identical to that observed in the analysis of consecutive blank 
samples (see above), demonstrating once more that no carryover effect is present. 
 
Valproic acid 
Valproic acid is a pharmaceutical compound mostly used as an antiepileptic. The therapeutic range 
reported in the scientific literature ranges from 40 to 100 μg/mL (Table 2). These concentrations 
are extremely high in comparison with the range investigated in this study. On the other hand, the 
addition of many substances in high concentration may create unrealistic perturbing effects on the 
method performances. Therefore, excessive analyte concentrations were avoided and, for valproic 
acid, only selectivity and carryover effects were evaluated. In both cases, the S/N value was lower 
than 3, successfully satisfying the acceptance requisite. In general, the present screening method 
proved reliable for determining the presence or absence of valproic acid in real blood samples, but 
for quantitation, a specific method was developed and validated [44].  
Case reports 
Our laboratory is continuously using the present screening method for the analysis of acute 
intoxications and postmortem blood samples. In most cases, one or more of the molecules 
included in this screening are identified. Afterwards, a confirmation analysis is usually performed. 
Some interesting cases of multiple positive identifications are reported in the following examples, in 
order to demonstrate the practical usefulness and general applicability of this comprehensive 
screening method.  
 
Case 1 
A 16-year-old girl attempted suicide by throwing herself from the seventh floor of the building 
where she lived. She was immediately rescued and hospitalized at an intensive care unit (ICU), but 
after approximately 3 h she was declared dead. Screening analyses revealed the presence of 
fentanyl, lidocaine, and dihydrocodeine. No confirmation analysis was performed since all three 
drugs were part of the pharmacological treatment executed at the ICU. The SRM chromatogram 
obtained from the UHPLC–MS/MS experiment is shown in Fig. 2a. 
 
Case 2 
When arriving back at home after a night out, a man with previous episodes of drug addiction 
realized that he had lost the keys of his apartment. Therefore, he persuaded his neighbor to let him 
climb his balcony, but he fell down from the third floor and immediately died. His blood sample was 
found positive to clonazepam, 7-aminoclonazepam, buprenorphine, norbuprenorphine, 
dextromethorphan, diltiazem, paracetamol, and lidocaine. The corresponding SRM chromatogram 
is shown in Fig. 2b. The results of confirmation analyses were consistent with the screening, 
proving a state of acute intoxication due to the presence of clonazepam and buprenorphine. 
Furthermore, high levels of morphine (from abuse of heroin) were also detected with a specific 
procedure for drugs of abuse, in coherence with the presence of dextromethorphan and 
paracetamol, commonly used as heroin adulterants. 
 
Case 3 
A 54-year-old man was found dead in his apartment. Due to his previous poor health conditions, 
the death was initially attributed to natural causes. After a few days, two men and one woman were 
arrested for having used the credit card of the deceased man the same night of his death. The 
prosecution also demonstrated that two of them took the victim out for dinner that night. Our 
laboratory was asked to verify if the blood of the deceased man contained any drug and, in case, if 
the concentration was allegedly lethal. Delorazepam, bromazepam, diazepam, and lormetazepam 
were found in the blood samples, as shown in Fig. 2c. The quantitative results from confirmation 
analyses suggested a past exposure to benzodiazepines and a recent administration of 
lormetazepam, found at 9 ng/mL concentration. Afterwards, the arrested did not challenge the 
results and admitted to have given a unspecified sleeping drug to the victim. 
 
Case 4 
A 57-year-old man died after a sexual intercourse with a prostitute. The analysis of his blood 
revealed the presence of sildenafil. The confirmation analysis determined the drug at a 
concentration of 29 ng/mL. The corresponding SRM chromatogram is shown in Fig. 2d. 
 
Case 5 
Blood screening analysis of a deceased old woman was requested to our laboratory because the 
nurse who assisted the woman was suspected of having caused her death by giving a wrong 
therapy or dosage. Our screening revealed the presence in the blood of quetiapine, paracetamol, 
mirtazapine, bromazepam, lormetazepam, and haloperidol, but the confirmation analyses indicated 
that blood concentrations were within the therapeutic range for all drugs. The corresponding SRM 




The development of UHPLC technology and fast MS/MS electronics has recently expanded the 
differentiation between screening procedures and confirmation methods. While the latter should 
achieve as much specificity and accuracy as possible, screening procedures are currently 
addressed to the accomplishment of high efficiency and high throughput objectives, even to the 
detriment of some sensitivity, trueness, and selectivity. Accordingly, the present study has been 
focused on the development of a fit-for-purpose analytical method, in order to detect in blood a 
large set of pharmaceutical substances selected among the ones most frequently found in acute 
intoxications and authoptic reports in Italy. The choice of a very simple and unselective preliminary 
sample treatment was coherent with the needs of both providing fast processing and reporting in 
the cases of acute intoxication, when the adoption of prompt and correct medical treatments may 
save the patient’s life, and expanding as much as possible the range of drugs included in a single 
screening. On the other hand, the most common drugs of abuse were not included in our analytical 
procedure since rapid screening is commonly provided by immunochemical tests, widely available 
in most clinical laboratories and emergency rooms, or by comprehensive LC–MS/MS procedures, 
recently introduced in several forensic laboratories, including ours, where all the most common 
drugs of abuse are screened on 0.1-ml blood sample. The effective use of the present method in 
our daily laboratory practice, some examples of which are reported in this study, demonstrates that 
the posed objectives were fully accomplished since (1) the entire procedure, from blood sampling 
to completion of the analysis, can be performed in less than 30 min; this is the key issue of the 
present method that proved to be of crucial importance in the cases of acute intoxication and 
urgent need of appropriate therapy setting; (2) multiple positive identification of active drugs are 
frequently met; (3) the therapeutic concentrations of all screened drugs largely exceed the LOD 
and LOQ experimental values of the method, while in most cases of acute intoxication the blood 
concentrations are even higher; (4) for the majority of screened drugs, the precision of quantitative 
determinations is satisfactory, assuring good repeatability on different blood samples, while the 
scarce accuracy recorded for some analytes is corrected by the subsequent confirmation analyses; 
and (5) the method is flexible and easily susceptible of further expansion to encompass more 
drugs, either new or becoming important in the forensic investigations.  
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Precursor Ion DP 
(V) 




















1 Alfentanil 3.4 417.0 +52  164.9 47 16  268.3 24 8 
2 Alprazolam 4.7 309.0 +77  205.1 56 9  280.9 36 12 
3 Amisulpride 2.1 370.0 +52  195.9 55 8  112.0 33 13 
4 Amitriptyline 4.2 278.0 +82  233.1 24 10  90.9 32 10 
5 Amobarbital 4.0 225.0 42  42.1 50 11  182.1 17 8 





 284.9 36 13  
287.1 34 12 
7 Atenolol 1.3 267.1 +74  145.0 33 13  190.3 26 9 
8 Barbital 2.3 183.2 70  42.1 43 15  140.1 16 6 
9 Biperiden 3.9 312.0 +55  98.1 31 47  70.3 68 13 





 182.2 42 8  
182.0 43 16 
11 Buprenorphine 3.7 468.0 +54  55.1 91 10  414.3 48 10 
12 Bupropion 3.0 240.0 +63  184.1 17 14  130.9 37 11 
13 Buspiron 3.2 386.0 +50  95.1 70 8  150.1 40 11 
14 Carbamazepine 4.3 237.0 +190  194.1 26 17  193.1 46 9 
15 Chlorpromazine 4.3 319.0 +40  86.1 25 13  58.0 63 8 
16 Citalopram 3.5 325.0 +88  262.0 26 12  109.1 34 10 
17 Clonazepam 4.7 316.0 +91  214.2 51 17  269.7 34 10 
18 Clotiazepam 5.7 319.0 +70  154.0 38 14  291.0 30 14 
19 Clozapine 3.3 326.9 +72  270.0 31 12  192.1 57 9 
20 Delorazepam 5.2 304.9 +27  139.9 39 21  242.1 37 11 
21 Demoxepam 3.8 285.1 80  241.1 20 10  152.1 24 11 
22 Desalkylflurazepam 4.9 289.0 +79  139.9 38 12  226.0 38 16 
23 Dextromethorphan 3.4 272.2 +46  171.1 50 15  215.1 34 10 
24 Diazepam 5.6 285.0 +51  154.0 36 7  193.1 43 15 
25 Dihydrocodeine 1.6 302.2 +70  199.1 42 9  128.1 75 11 
26 Diltiazem 3.7 415.0 +14  178.0 32 15  150.0 58 16 
27 Diphenhydramine 3.5 256.1 +80  165.1 54 14  167.0 20 8 
28 Embutramide 4.8 294.0 +57  121.0 34 11  191.0 22 17 
29 Fentanyl 3.5 337.0 +175  188.2 31 9  105.1 50 10 
30 Flunitrazepam 5.0 314.0 +35  268.2 36 11  239.1 47 11 
31 Fluoxetine 4.3 310.1 +36  44.1 48 5  148.0 12 14 





 316.9 34 13  
316.9 26 12 
33 Haloperidol 3.7 376.0 +45  123.0 53 16  164.9 33 13 
34 Ibuprofen 5.9 205.0 42  161.1 10 7  159.0 9 13 
35 Ketamine 2.3 238.0 +100  125.0 38 11  207.1 20 9 
36 Ketoprofen 5.2 255.0 +38  209.1 19 9  104.9 32 11 
37 Ketorolac 4.5 256.2 +42  105.0 25 12  77.0 62 11 
38 Levamisole 1.7 204.9 +52  178.1 30 8  123.0 39 16 
39 Levomepromazine 4.2 329.0 +22  100.0 25 18  58.1 53 9 
40 Lidocaine 2.2 235.1 +230  86.1 27 11  58.0 47 14 
41 Loperamide 4.7 477.0 +12  266.1 34 14  210.1 64 14 





 277.0 34 12  
303.0 22 13 





 288.9 30 13  
291.0 28 12 
44 Methadone 4.2 310.0 +240  265.1 20 10  105.0 33 9 
45 Methylphenidate 2.6 234.2 +66  84.3 24 6  56.1 63 7 
46 Metoclopramide 2.3 299.9 +23  184.0 41 18  227.0 26 19 
47 Mianserin 3.5 265.0 +122  208.1 27 14  58.1 45 14 
48 Midazolam 3.5 325.9 +14  291.0 38 12  249.1 50 11 
49 Mirtazapine 2.6 266.0 +28  195.0 36 9  72.0 26 11 
50 Nitrazepam 4.5 282.1 +30  236.0 32 11  180.0 50 9 
51 Norbuprenorphine 3.1 414.2 +47  187.0 50 15  101.3 46 8 
52 Nordiazepam 4.9 271.0 +71  140.0 37 13  208.0 38 18 
53 Norfentanyl 2.3 233.2 +77  84.3 23 7  55.0 49 10 
54 Norketamine 2.2 224.0 +28  125.0 37 10  207.0 17 20 
55 Olanzapine 1.8 313.0 +58  256.1 33 11  198.0 52 9 
56 Omeprazole 3.3 345.9 +50  198.0 15 8  136.0 49 11 
57 Oxcarbamazepine 3.7 252.9 +50  180.1 40 15  208.0 28 9 
58 Oxybutynin 4.3 358.0 +20  124.0 27 5  72.1 52 7 
59 Oxycodone 1.8 316.0 +18  241.0 38 10  256.1 35 11 
60 Oxymorphone 1.0 302.2 +80  284.0 28 12  227.2 38 10 
61 Paracetamol 1.5 152.0 +32  110.0 22 15  65.0 39 11 
62 Paroxetine 3.8 329.9 +19  192.0 29 16  123.1 33 14 
63 Pentazocine 3.1 286.2 +30  175.2 35 6  173.0 40 8 
64 Pericyazine 3.7 366.0 +14  142.1 30 11  114.0 37 14 
65 Phenacetin 3.5 180.0 +77  110.1 29 15  138.0 21 16 
66 Phenobarbital 3.2 231.2 70  42.0 43 13  188.0 14 8 
67 Promazine 3.9 285.1 +12  86.1 24 13  58.1 57 7 
68 Quetiapine 3.5 384.1 +70  221.1 49 9  253.1 31 11 
69 Ramipril 4.1 417.2 +20  234.1 29 10  91.1 86 14 
70 Remifentanil 2.9 377.1 +43  112.9 39 12  317.2 22 14 
71 Risperidone 3.1 411.1 +18  191.0 40 8  110.0 66 19 
72 Scopolamine 1.8 304.1 +30  138.1 27 13  156.1 22 9 
73 Secobarbital 4.3 237.2 19  41.9 45 10  194.2 17 8 
74 Sildenafil 3.6 475.2 +59  58.1 74 10  99.9 36 14 
75 Sufentanil 4.0 387.2 +26  238.1 27 8  355.2 27 16 
76 Tadalafil 4.8 390.0 +59  268.0 17 11  169.1 47 15 
77 Telmisartan 4.7 512.2 +60  497.0 47 20  276.0 62 11 
78 Tramadol 2.6 264.1 +35  58.1 46 11  246.1 15 14 
79 Trazodone 3.2 372.1 +125  176.0 33 16  148.0 43 7 
80 Triazolam 4.8 343.0 +36  308.0 37 13  314.9 39 13 
81 Valproic Acid 4.8 142.9 51  142.9 30 10     
82 Vardenafil 3.3 489.2 +27  151.0 52 7  312.0 52 11 
83 Venlafaxine 3.1 278.1 +55  58.0 22 10  260.2 17 11 
84 Zolpidem 2.9 308.1 +50  92.0 63 12  220.1 60 9 





 245.0 25 10  
246.9 25 11 




+74  227.0 35 10  135.2 
35 12 
88 7-aminonitrazepam 1.8 252.0 +91  120.9 35 18  94.0 48 15 




+80  185.1 42 14  212.2 
47 14 
IS Cocaine-d3 (COC-d3) 2.8 307.2 +80  185.1 28 8  85.1 47 14 
IS Coumachlor (COU) 6.3 343.0 +37  163.0 20 8  285.0 30 10 
 

















1 Alfentanil A COC-d3 2  75 0.994 0.13 0.43 9  10 
2 Alprazolam A NIT-d5 2  75 0.999 0.25 0.82 5  50 
3 Amisulpride B COC-d3 10  150 0.997 0.13 0.45 50  400 
4 Amitriptyline B COC-d3 10  150 0.994 0.24 0.81 80  200 
5 Amobarbital C ALT 20  300 0.997 6.00 20.0 2  12 (µg/mL) 
6 Aripiprazole B CCL 10  150 0.992 0.68 2.25 50  350 
7 Atenolol B COC-d3 10  150 0.991 0.49 1.65 120  870 
8 Barbital C ALT 50  300 0.997 15.0 50.0 5  30 (µg/mL) 
9 Biperiden A CCL 2  75 0.995 0.25 0.83 4  6 
10 Bromazepam B NIT-d5 10  150 0.994 1.00 3.33 50  170 
11 Buprenorphine A COC-d3 2  75 0.991 0.60 2.00 0.2  0.7 
12 Bupropion A CCL 2  75 0.998 0.13 0.42 25  100 
13 Buspiron C COC-d3 20  300 0.992 0.81 2.68 0.9  5 (µg/mL) 
14 Carbamazepine C NIT-d5 20  300 0.993 0.96 3.19 4  12 (µg/mL) 
15 Chlorpromazine B CCL 10  150 0.994 0.59 1.96 2  122 
16 Citalopram B COC-d3 10  150 0.996 0.28 0.93 20  200 
17 Clonazepam A NIT-d5 2  75 0.995 0.33 1.09 20  80 
18 Clotiazepam B NIT-d5 10  150 0.991 0.16 0.54 10  700 
19 Clozapine B NIT-d5 10  150 0.986 0.76 2.53 350  450 
20 Delorazepam A NIT-d5 2  75 0.997 0.13 0.44 12  14.5 
21 Demoxepam C ALT 20  300 0.993 3.33 11.1 0.4  4 (µg/mL) 
22 Desalkylflurazepam A NIT-d5 5  75 0.996 0.87 2.90 40  60 
23 Dextromethorphan A COC-d3 2  75 0.997 0.13 0.43 1  8 
24 Diazepam B NIT-d5 10  150 0.990 0.17 0.57 100  1000 
25 Dihydrocodeine B COC-d3 10  150 0.985 0.50 1.65 72  146 
26 Diltiazem B COC-d3 10  150 0.997 0.40 1.35 50  200 
27 Diphenhydramine B COC-d3 10  150 0.994 0.50 1.67 100  1000 
28 Embutramide C CCL 20  300 0.991 0.92 3.07 3 – 12.1 (µg/mL) 
29 Fentanyl A COC-d3 2  75 0.993 0.19 0.64 0.1  5 
30 Flunitrazepam A NIT-d5 2  75 0.997 0.38 1.27 1.5  20 
31 Fluoxetine B COC-d3 10  150 0.988 0.67 2.24 150  500 
32 Flurazepam A NIT-d5 2  75 0.998 0.18 0.60 0.5  30 
33 Haloperidol A CCL 2  75 0.999 0.12 0.39 5  40 
34 Ibuprofen C ALT 50  300 0.994 13.9 46.5 20  30 (µg/mL) 
35 Ketamine C CCL 20  300 0.998 0.24 0.80 0.64  2.2 (µg/mL) 
36 Ketoprofen C CCL 20  300 0.991 0.71 2.35 6  15 (µg/mL) 
37 Ketorolac C CCL 50  300 0.989 6.74 22.5 0.22  3.5 (µg/mL) 
38 Levamisole C NIT-d5 20  300 0.998 0.25 0.84 0.7  1.5 (µg/mL) 
39 Levomepromazine B COC-d3 10  150 0.994 0.37 1.23 15  140 
40 Lidocaine C COC-d3 20  300 0.992 4.80 16.0 2  5 (µg/mL) 
41 Loperamide A CCL 2  75 0.996 0.26 0.88 2  3.98 
42 Lorazepam B NIT-d5 10  150 0.993 0.50 1.68 5  240 
43 Lormetazepam A NIT-d5 2  75 0.998 0.39 1.29 6  16 
44 Methadone B COC-d3 10  150 0.997 2.70 9.01 50  1000 
45 Methylphenidate A COC-d3 2  75 0.994 0.68 2.60 8  58 
46 Metoclopramide B COC-d3 10  150 0.994 0.10 0.34 40  130 
47 Mianserin A NIT-d5 5  75 0.998 1.33 4.44 15  70 
48 Midazolam B NIT-d5 10  150 0.994 0.45 1.49 10  147 
49 Mirtazapine A NIT-d5 2  75 0.998 0.09 0.31 20  100 
50 Nitrazepam A NIT-d5 2  75 0.998 0.38 1.26 30  70 
51 Norbuprenorphine B COC-d3 25  150 0.987 5.47 18.2 1  2.6 
52 Nordiazepam C NIT-d5 20  300 0.999 0.17 0.57 0.17  1.84 (µg/mL) 
53 Norfentanyl A COC-d3 2  75 0.991 0.42 1.41 0.1  5 
54 Norketamine C CCL 20  300 0.996 0.30 1.00 0.64  2.2 (µg/mL) 
55 Olanzapine A NIT-d5 5  75 0.996 0.97 3.23 10  75 
56 Omeprazole A COC-d3 2  75 0.998 0.09 0.29 0.23  1.66 
57 Oxcarbamazepine C NIT-d5 20  300 0.995 0.57 1.90 12  30 (µg/mL) 
58 Oxybutynin A CCL 2  75 0.993 0.22 0.74 10  20 
59 Oxycodone A COC-d3 5  75 0.995 0.95 3.17 20  50 
60 Oxymorphone B COC-d3 10  150 0.993 0.54 1.80 100  700 
61 Paracetamol C CCL 20  300 0.997 1.73 5.76 10  20 (µg/mL) 
62 Paroxetine A CCL 5  75 0.995 1.03 3.45 10  75 
63 Pentazocine B NIT-d5 10  150 0.991 0.30 1.00 100  300 
64 Pericyazine A NIT-d5 2  75 0.994 0.22 0.73 5  30 
65 Phenacetin C COC-d3 20  300 0.997 0.48 1.60 0.2  7 (µg/mL) 
66 Phenobarbital C ALT 20  300 0.997 3.45 1.49 2  30 (µg/mL) 
67 Promazine B COC-d3 10  150 0.995 0.60 2.00 10  400 
68 Quetiapine B NIT-d5 10  150 0.993 0.52 1.72 50  500 
69 Ramipril B COC-d3 10  150 0.996 0.71 2.38 6  260 
70 Remifentanil A COC-d3 2  75 0.997 0.06 0.21 1  40 
71 Risperidone A NIT-d5 2  75 0.998 0.13 0.44 10  90 
72 Scopolamine A COC-d3 2  75 0.997 0.25 0.82 0.3  2 
73 Secobarbital C ALT 20  300 0.998 9.68 2.26 2  10 (µg/mL) 
74 Sildenafil B NIT-d5 10  150 0.995 1.33 4.44 280  450 
75 Sufentanil A COC-d3 2  75 0.994 0.04 0.13 0.5  11 
76 Tadalafil A NIT-d5 5  75 0.996 1.44 4.81 4.9  13.7 
77 Telmisartan C NIT-d5 20  300 0.998 2.74 9.13 0.51  3.28 (µg/mL) 
78 Tramadol B COC-d3 10  150 0.998 2.21 7.35 100  800 
79 Trazodone C NIT-d5 20  300 0.997 0.15 0.50 0.65  1.5 (µg/mL) 
80 Triazolam A NIT-d5 2  75 0.998 0.24 0.80 6  17 
81 Valproic  Acid  C - - - - - 40  100 (µg/mL) 
82 Vardenafil A NIT-d5 5  75 0.993 1.43 4.76 2.8  17 
83 Venlafaxine B COC-d3 10  150 0.997 0.13 0.43 250  750 
84 Zolpidem B NIT-d5 10  150 0.994 0.17 0.55 80  150 
85 Zopiclone A NIT-d5 2  75 0.999 0.52 1.72 10  50 
86 7-aminoclonazepam A NIT-d5 2  75 0.998 0.12 0.41 20  70 
87 7-aminoflunitrazepam B NIT-d5 10  150 0.997 0.47 1.55 20  500 
88 7-aminonitrazepam A NIT-d5 2  75 0.999 0.33 1.09 18  53 
 
Table 2 For each compound, the corresponding working solution and internal standard, linearity range, squared 
correlation coefficient, LOD and LOQ values, and therapeutic level are reported 

































1 Alfentanil 5 40.0 38.1 58.7 58.7 25 12.1 +10.6 51.8 61.8 75 3.4 +6.5 71.8 51.1 
2 Alprazolam 5 23.8 +11.8 54.8 42.6 25 14.5 +8.8 49.7 44.1 75 9.9 +1.7 66.7 32.0 
3 Amisulpride 25 23.3 +3.3 57.4 22.1 75 4.5 19.0 66.5 14.3 150 2.9 10.5 74.4 12.8 
4 Amitriptyline 25 16.0 +28.6 52.5 42.6 75 5.6 20.5 57.9 40.3 150 6.6 2.7 67.3 30.3 
5 Amobarbital 50 24.5 +137.0 62.2 37.4 150 12.7 +136.8 63.2 43.7 300 9.9 +167.3 72.2 43.4 
6 Aripiprazole 25 16.1 +29.6 53.4 42.6 75 9.0 15.1 59.1 40.3 150 4.9 +3.3 67.3 30.3 
7 Atenolol 25 14.7 +138.7 47.6 26.7 75 7.4 +74.7 56.1 23.7 150 6.5 +105.5 69.7 23.5 
8 Barbital 50 19.7 +92.4 59.8 +17.6 150 5.3 +102.8 60.7 3.4 300 8.2 +114.5 71.9 2.3 
9 Biperiden 5 34.6 33.5 53.9 24.3 25 11.3 39.9 46.3 38.1 75 5.2 29.8 63.9 21.0 
10 Bromazepam 25 12.3 +36.3 50.6 14.9 75 7.2 +27.8 57.4 3.8 150 3.5 +29.3 68.8 +3.3 
11 Buprenorphine 5 35.8 +23.3 55.9 46.5 25 15.9 +13.9 43.2 48.2 75 7.5 +42.4 56.0 47.3 
12 Bupropion 5 15.2 +3.0 58.5 30.1 25 12.9 20.8 48.9 39.6 75 4.8 8.2 70.9 20.2 
13 Buspiron 50 21.7 8.2 56.2 30.6 150 5.9 +4.7 58.8 30.1 300 6.7 1.5 69.3 22.5 
14 Carbamazepine 50 28.0 51.2 39.9 62.4 150 8.5 +8.5 41.9 63.9 300 15.4 +16.7 46.9 61.1 
15 Chlorpromazine 25 27.5 +10.6 59.4 51.3 75 10.9 29.3 59.4 53.7 150 8.3 21.7 70.6 47.8 
16 Citalopram 25 15.2 +19.3 57.9 29.6 75 6.2 5.5 63.7 30.2 150 3.8 +7.1 70.8 30.2 
17 Clonazepam 5 22.7 +15.2 56.9 40.6 25 14.0 +0.1 43.0 39.2 75 9.1 5.6 73.0 26.3 
18 Clotiazepam 25 18.2 +23.6 55.9 52.6 75 8.8 +3.0 63.9 50.3 150 5.9 2.8 73.8 43.7 
19 Clozapine 25 20.4 +25.4 52.9 42.3 75 11.6 +8.4 58.7 36.5 150 8.1 +1.5 64.8 39.5 
20 Delorazepam 5 21.7 +22.1 53.2 34.4 25 14.6 +1.7 48.9 36.3 75 10.8 +2.6 66.5 21.1 
21 Demoxepam 50 20.7 21.2 59.3 6.9 150 8.2 9.2 59.1 23.2 300 8.7 +7.5 70.3 20.6 
22 Desalkylflurazepam 5 16.7 +26.7 55.1 37.1 25 13.7 +3.4 48.9 40.8 75 10.8 0.4 69.7 24.3 
23 Dextromethorphan 5 29.2 16.2 56.5 32.5 25 15.5 14.9 45.7 41.5 75 4.3 +8.3 65.0 31.5 
24 Diazepam 25 17.2 +34.0 53.6 47.5 75 8.4 +9.4 61.2 44.4 150 6.0 +8.0 70.4 36.1 
25 Dihydrocodeine 25 19.4 +33.8 50.4 20.1 75 3.7 +15.5 59.5 2.6 150 1.8 +27.2 69.7 5.6 
26 Diltiazem 25 14.5 +15.3 54.2 36.9 75 8.0 1.0 60.5 34.3 150 2.6 +6.4 68.3 32.2 
27 Diphenhydramine 25 19.4 +18.2 56.9 18.3 75 3.7 22.9 60.3 26.3 150 4.5 2.9 69.7 25.6 
28 Embutramide 50 21.2 20.8 60.9 46.5 150 4.8 8.4 62.2 48.1 300 6.2 7.7 76.2 39.6 
29 Fentanyl 5 31.3 8.2 53.4 36.6 25 12.2 0.3 50.2 34.2 75 8.2 +9.0 68.2 29.0 
30 Flunitrazepam 5 19.5 +25.3 59.4 27.0 25 13.8 +14.4 51.2 30.7 75 10.2 +5.7 69.8 16.0 
31 Fluoxetine 25 24.2 29.1 42.8 62.1 75 8.8 +5.3 47.9 60.4 150 22.5 42.1 54.4 56.3 
32 Flurazepam 5 29.1 +0.2 55.6 41.7 25 15.9 +9.4 56.6 41.0 75 11.5 0.3 65.4 38.5 
33 Haloperidol 5 13.3 3.6 51.6 27.5 25 13.0 23.6 43.1 30.8 75 5.3 14.2 61.7 16.7 
34 Ibuprofen 50 16.5 +397.2 68.9 19.3 150 10.0 +354.5 65.2 42.7 300 8.4 +364.0 72.5 39.8 
35 Ketamine 50 32.4 53.2 60.6 20.1 150 7.8 35.2 62.2 21.7 300 8.0 26.8 80.0 16.5 
36 Ketoprofen 50 17.1 26.0 52.6 12.9 150 7.5 3.1 56.1 24.8 300 6.6 +15.2 70.9 18.5 
37 Ketorolac 50 17.3 29.2 52.9 24.5 150 5.5 +22.7 54.2 25.6 300 5.4 +47.3 68.8 19.7 
38 Levamisole 50 30.0 35.9 61.0 14.2 150 12.2 +0.1 62.1 19.5 300 12.1 14.5 79.3 16.8 
39 Levomepromazine 25 22.6 +20.7 43.0 42.2 75 4.7 9.2 48.4 40.3 150 9.3 16.9 57.1 40.6 
40 Lidocaine 50 26.5 11.7 65.6 11.4 150 9.5 6.5 58.6 22.4 300 10.3 +3.6 86.5 9.8 
41 Loperamide 5 26.7 16.2 57.2 38.2 25 15.1 31.1 49.8 39.9 75 6.8 14.9 68.3 22.8 
42 Lorazepam 25 12.9 +25.3 49.4 29.7 75 8.3 +15.9 57.6 29.1 150 2.2 +24.4 66.9 22.2 
43 Lormetazepam 5 21.4 +16.1 53.2 50.3 25 14.8 +5.0 48.6 49.5 75 9.6 +6.7 65.5 37.3 
44 Methadone 25 23.3 +37.3 55.3 13.5 75 4.9 +13.0 69.5 16.9 150 8.8 +25.1 81.4 4.6 
45 Methylphenidate 5 35.5 40.6 56.9 34.3 25 11.9 30.4 48.6 41.4 75 4.1 28.5 68.5 27.1 
46 Metoclopramide 25 13.5 +19.3 58.3 10.1 75 5.4 10.0 66.7 6.4 150 2.2 2.0 77.4 4.3 
47 Mianserin 5 13.9 7.5 62.0 36.7 25 18.2 21.5 57.3 38.5 75 9.5 24.6 64.9 35.6 
48 Midazolam 25 13.9 +33.1 53.7 46.0 75 9.2 +18.1 59.5 46.9 150 7.7 +3.6 69.5 41.5 
49 Mirtazapine 5 19.2 1.7 58.7 25.5 25 13.8 +1.6 51.2 39.7 75 8.1 1.6 69.9 30.4 
50 Nitrazepam 5 17.3 +35.5 55.6 29.1 25 12.9 +17.6 50.1 37.2 75 7.1 +11.1 69.9 19.7 
51 Norbuprenorphine -     25 21.9 +23.5 22.1 88.3 75 53.2 82.4 25.9 86.1 
52 Nordiazepam 50 24.6 +11.2 53.8 50.0 150 7.7 +46.1 55.0 52.1 300 10.4 +35.9 68.9 43.1 
53 Norfentanyl 5 43.8 47.6 40.6 66.5 25 18.1 +21.7 35.8 66.9 75 26.9 43.5 46.2 56.8 
54 Norketamine 50 24.9 37.8 57.9 20.5 150 9.4 30.1 60.3 24.1 300 8.6 25.3 79.4 13.7 
55 Olanzapine 5 16.0 23.8 38.0 +9.9 25 15.9 26.5 32.5 67.5 75 13.9 31.5 42.5 20.5 
56 Omeprazole 5 21.6 +37.4 54.1 28.6 25 15.1 +46.9 49.4 36.0 75 5.1 +48.0 69.8 12.5 
57 Oxcarbazepine 50 22.5 +9.4 47.8 39.8 150 9.0 +35.6 49.6 44.0 300 12.4 +21.9 64.3 34.4 
58 Oxybutynin 5 20.2 4.6 60.9 41.4 25 13.8 31.0 53.7 45.9 75 9.2 13.9 68.9 34.5 
59 Oxycodone 5 17.1 +23.2 55.8 19.5 25 8.5 +23.8 50.0 20.1 75 4.9 +23.5 68.7 +8.1 
60 Oxymorphone 25 21.3 +25.6 43.6 37.6 75 4.6 5.6 62.4 32.8 150 6.4 +20.5 65.1 23.8 
61 Paracetamol 50 22.2 33.4 56.4 28.1 150 6.1 34.5 59.5 32.6 300 6.4 +0.5 77.0 21.9 
62 Paroxetine 5 38.3 67.2 41.5 71.0 25 22.9 27.7 35.0 75.8 75 36.5 69.5 42.9 70.8 
63 Pentazocine 25 19.9 +23.7 55.2 13.9 75 11.1 +4.6 58.5 21.0 150 4.0 6.5 65.6 20.9 
64 Pericyazine 5 30.5 +63.8 42.8 16.0 25 16.4 +81.3 43.0 15.0 75 6.1 +23.4 48.3 12.2 
65 Phenacetin 50 19.5 23.9 59.1 36.8 150 3.6 5.6 60.7 32.8 300 8.0 6.9 72.7 28.6 
66 Phenobarbital 50 22.5 +59.8 60.2 20.2 150 10.0 +71.3 59.9 33.9 300 8.4 +95.7 70.7 32.2 
67 Promazine 25 32.5 +40.3 41.3 48.5 75 3.6 +2.1 41.8 51.8 150 11.8 2.8 47.5 50.8 
68 Quetiapine 25 8.5 +20.9 53.9 40.3 75 12.8 +10.9 63.9 38.1 150 6.3 9.5 69.5 32.8 
69 Ramipril 25 16.2 +29.0 50.8 44.6 75 5.3 +10.8 58.8 45.8 150 4.3 +24.0 67.6 40.5 
70 Remifentanil 5 22.3 7.9 56.0 47.7 25 12.5 8.3 48.8 49.8 75 4.4 0.7 67.3 34.0 
71 Risperidone 5 25.4 15.3 61.1 25.9 25 18.7 14.9 55.6 33.3 75 10.3 28.7 64.4 60.5 
72 Scopolamine 5 22.4 +29.8 59.6 1.6 25 9.4 +26.4 51.5 12.9 75 2.7 +37.7 71.4 +22.2 
73 Secobarbital 50 21.2 +62.9 65.0 35.0 150 10.1 +62.7 62.8 45.4 300 8.5 +91.3 70.1 44.2 
74 Sildenafil 25 7.7 +76.1 56.2 18.8 75 10.3 +65.1 64.9 4.2 150 8.4 +49.7 73.9 1.4 
75 Sufentanil 5 25.9 8.4 56.4 35.2 25 14.4 18.6 49.6 39.3 75 5.4 6.8 68.2 27.2 
76 Tadalafil 5 19.0 +43.0 55.9 21.9 25 8.5 +27.0 52.4 23.9 75 11.1 +25.2 70.3 2.7 
77 Telmisartan 50 31.1 +106.0 66.6 73.1 150 2.5 +172.8 53.3 82.5 300 10.8 +80.3 54.9 82.9 
78 Tramadol 25 21.0 +9.9 55.9 15.7 75 5.1 13.8 64.1 16.6 150 7.4 8.3 74.9 14.0 
79 Trazodone 50 19.5 +0.1 58.5 46.2 150 12.8 +22.1 62.5 43.5 300 11.0 3.9 73.9 34.3 
80 Triazolam 5 19.8 +9.5 58.3 44.4 25 13.1 +7.3 49.7 46.6 75 12.6 +2.3 65.1 33.8 
82 Vardenafil 5 22.0 +2.0 60.3 70.8 25 18.0 +58.1 51.5 67.2 75 12.5 +11.6 63.8 65.2 
83 Venlafaxine 25 22.6 +19.4 56.3 27.8 75 5.2 8.1 64.1 28.1 150 5.6 7.1 72.9 26.6 
84 Zolpidem 25 3.2 +3.8 60.0 14.3 75 9.5 7.4 68.7 15.1 150 5.4 15.9 72.3 17.5 
85 Zopiclone 5 16.4 +49.3 58.1 1.2 25 16.8 +52.6 53.9 6.0 75 8.7 +25.0 68.5 +15.3 
86 7- aminoclonazepam 5 28.7 22.2 53.1 66.0 25 15.0 +13.3 46.8 69.2 75 10.0 4.8 63.7 59.4 
87 7-aminoflunitrazepam 25 19.9 +28.7 60.7 51.0 75 12.2 +21.1 65.2 55.7 150 7.8 +1.5 70.8 54.7 






Table 3 For each compound, intra-assay precision, trueness, recovery and matrix effect at low, medium and high concentration are reported 
 
 
Fig. 1 SRM chromatograms recorded from a whole blood sample spiked with all analytes at 50 ng/mL 
concentration. For each analyte, labeled by the progressive number assigned in Table 1, only the target ion is 
shown. a–d SRM chromatograms for ESI+ ion mode. e SRM chromatogram for ESI− ion mode 
 
Fig. 2 SRM chromatograms obtained from UHPLC–MS/MS experiments. a Case report 1. b Case report 2. c Case 
report 3. d Case report 4. e Case report 5 
